221 related articles for article (PubMed ID: 25813264)
1. [Empagliflozin - the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type].
Prázný M; Slíva J
Vnitr Lek; 2015 Feb; 61(2):175-8. PubMed ID: 25813264
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin for the treatment of type 2 diabetes.
Jahagirdar V; Barnett AH
Expert Opin Pharmacother; 2014 Nov; 15(16):2429-41. PubMed ID: 25301180
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin: A Review in Type 2 Diabetes.
Frampton JE
Drugs; 2018 Jul; 78(10):1037-1048. PubMed ID: 29946963
[TBL] [Abstract][Full Text] [Related]
4. Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.
White JR
Ann Pharmacother; 2015 May; 49(5):582-98. PubMed ID: 25712444
[TBL] [Abstract][Full Text] [Related]
5. [New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes].
Rušavý Z
Vnitr Lek; 2014 Nov; 60(11):926-7, 929-30. PubMed ID: 25600037
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
Blevins T
Expert Opin Drug Saf; 2015 May; 14(5):789-93. PubMed ID: 25789798
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Dailey GE
Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin for the treatment of Type 2 diabetes.
Gangadharan Komala M; Mather A
Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
Jain RK
Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
[TBL] [Abstract][Full Text] [Related]
11. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
Muscelli E; Astiarraga B; Barsotti E; Mari A; Schliess F; Nosek L; Heise T; Broedl UC; Woerle HJ; Ferrannini E
Diabetologia; 2016 Apr; 59(4):700-8. PubMed ID: 26704626
[TBL] [Abstract][Full Text] [Related]
12. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
Jordan J; Tank J; Heusser K; Heise T; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
J Am Soc Hypertens; 2017 Sep; 11(9):604-612. PubMed ID: 28757109
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
14. [EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):472-9. PubMed ID: 26638450
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
Hu J; Zou P; Zhang S; Zhou M; Tan X
Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 inhibitors: new reports.
Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
[TBL] [Abstract][Full Text] [Related]
18. Impact of EMPA-REG OUTCOME
Naing S; Poliyedath A; Khandelwal S; Sigala T
Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
[TBL] [Abstract][Full Text] [Related]
19. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
20. ▼ Empagliflozin, diabetes and outcomes.
Drug Ther Bull; 2016 Jul; 54(7):78-81. PubMed ID: 27417322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
